(nAbs) targeting the major envelope glycoprotein gp350/220 (gp350). To date, eight gp350 epitopes have been 21
antibodies. We compared the candidate anti-gp350 antibodies to nAb-72A1 by: (1) testing their ability to detect 23 gp350 using ELISA, flow cytometry, and immunoblot; (2) sequencing their heavy and light chain 24 complementarity-determining regions (CDRs); (3) measuring the ability of each monoclonal antibody (mAb) to 25 neutralize EBV infection in vitro; and (4) mapping the gp350 amino acids bound by the mAbs using RepliTope 26 peptide microarrays. Eight antibodies recognized both denatured and non-denatured gp350, whereas five failed 27 to react with denatured gp350 but recognized native gp350, suggesting they recognized conformational 28 epitope(s). Sequence analysis of the heavy and light chain variable regions of the hybridomas identified 15 as 29 mAbs with novel CDR regions unique from those of nAb-72A1. Seven of the new mAbs neutralized EBV in 30 vitro, with HB20 and HB17 reducing EBV infection by 40% and >60%, and >30% and 80%, at 10 µg/ml and 31 50 µg/ml, respectively. Epitope mapping identified nine epitopes and defined their core residues, including two 32 unique immunodominant epitopes, 253 TPIPGTGYAYSLRLTPRPVSRFL 275 and 33 875 LLLLVMADCAFRRNLSTSHTYTTPPY 899 , and a novel nAb epitope 381 GAFASNRTFDIT 392 . This 34 study provides comprehensive in vitro mapping of the exact residues defining nine epitopes of EBV gp350. Our 35 findings will inform novel strategies to design optimal EBV vaccines capable of conferring broader protection 36 against the virus. 37
Introduction 52
Epstein-Barr virus (EBV) infection is the causal agent of acute infectious mononucleosis (9, 13). Persistent 53
EBV infection in immunodeficient individuals is associated with numerous epithelial and lymphoid 54 malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, Burkitt lymphoma, Hodgkin lymphoma, 55 and post-transplant lymphoproliferative diseases (PTLD) (24). Pre-existing antibodies provide the primary 56 defense against viral infection. Prophylactic prevention of EBV primary infection has mainly focused on 57 blocking the first step of viral entry by generating neutralizing antibodies (nAbs) that target EBV envelope 58 glycoproteins. Five glycoproteins in particular-gp350/220 (gp350), gp42, gH, gL, and gB-are required for 59 efficient infection of permissible host cells and have emerged as potential prophylactic targets (2, 3, 5, 20) . 60 EBV predominantly infects epithelial cells and B cells, reflecting the viral tropism and the cellular 61 ontogeny for EBV-associated malignancies (4). There are two schools of thought on how the initial EBV 62 transmission into the human host cells occurs. In the first infection model, the incoming virus engages with 63 ephrin receptor A2 via heterodimeric gH/gL, which triggers gB fusion with the epithelial cell membrane and 64 entry of the virus into the cytoplasm (4). This interaction is thought to occur in the oral mucosa, where the virus 65 undergoes lytic replication to release virions that subsequently infect B cells. In the alternative model, the 66 incoming virus binds to the host cell via complement receptor type 1 (CR1)/CD35 (17) and/or CR2/CD21 67 through its major immunodominant glycoprotein, gp350 (6). The interaction between gp350 and CD35 and/or 68 CD21 triggers viral adsorption, capping, and endocytosis into the B cell (31), which subsequently leads to the 69 heterotrimeric viral glycoproteins complex, gp42/gH/gL, binding to HLA class II molecules to activate gB 70 membrane fusion and entry. Because these two models are not necessarily mutually exclusive, and given that 71 both gp350 and gH/gL complex are important in initiating the first viral contact with host cells, use of nAbs that 72 target either gp350 or gH/gL complex, or both, may potently block incoming virus at the oral mucosa.
Nearly all EBV-infected individuals develop nAbs directed to the ectodomains of these glycoproteins (25, 74 36) . These antibodies can prevent neonatal infection, can protect against acute infectious mononucleosis in 75 adolescents, and can protect against several human lymphoid and epithelial malignancies associated with EBV 76 infection (7, 14, 23, 28) . Although numerous monoclonal antibodies (mAbs) have been generated against EBV 77 gp350 (11, 21, 34), only two murine mAbs, the non-neutralizing 2L10 and the neutralizing 72A1, have been 78 extensively characterized and made commercially available (11, 34) . Importantly, nAb-72A1 conferred short-79 term clinical protection against EBV transmission after transplantation in pediatric patients in a small phase I 80 clinical trial (8) . 81 EBV gp350 is the most immunogenic envelope glycoproteins on the virion. It is a type 1 membrane 82 protein that encodes for 907 amino acid (aa) residues. A single splice of the primary transcript deletes 197 83 codons and joins gp350 codons 501 and 699, in frame, to generate the gp220 messenger RNA. Both gp350 and 84 gp220 are comprised of the same 18-aa residue at the C terminus that is located within the viral membrane, a 85 25-aa residue at the transmembrane-spanning domain, and a large highly glycosylated N-terminal ectodomain, 86 aa 1-841 (32). The first 470 aa of gp350 are sufficient for binding CD21 in B cells, as demonstrated by a 87 truncated gp350 (aa 1-470) blocking the binding of EBV to B cells and reducing viral infectivity (8). The 88 gp350-binding domain on CD21 maps to N-terminal short consensus repeats (SCRs) 1 and 2, which also bind to 89 a bioactive fragment of complement protein 3 (C3d) (16, 18) . A soluble truncated EBV gp350 fragment (aa 1-90 470) and soluble CD21 SCR1 and SCR2 can block EBV infection and immortalization of primary B cells (32). 91
However, gp350 binding to CD35 is not restricted to N-terminal SCRs; it binds long homologous repeat regions 92 as well as . 93
The gp350 ectodomain is heavily glycosylated, with both N-and O-linked sugars, which accounts for over 94 half of the molecular mass of the protein. Currently there is only one crystal structure available for gp350, 95 comprised of a truncated structure between 4-443 aa, with at least 14 glycosylated arginines coating the protein 96 with sugars, with the exception of a single glycan-free patch (30). Mutational studies of several residues in the 97 glycan-free patch resulted in the loss of CD21 binding (30), suggesting that binding of CD35 and CD21 by 98 gp350 is mediated within this region. 99
There are at least eight unique CD21 binding epitopes located at the N-terminus of the gp350 ectodomain 100 (35); at least one of these epitopes (aa 142-161) is capable of eliciting nAbs (32, 35) . The aa residues 142-161 101 are also the binding site for nAb-72A1 (11, 30). Using gp350 synthetic peptides binding to CD21 on the surface 102 of a B cell line, an additional gp350 epitope was identified in the C-terminal region of gp350 (aa 822-841), 103
suggesting it is involved in EBV invasion of B cells (35) . The role of other epitopes in eliciting nAbs has not 104 been fully investigated. Furthermore, the exact aa residues that comprise the core binding sites for epitopes 105 capable of eliciting neutralizing and non-nAbs have not been determined. Mapping the EBV gp350 protein 106 residues that define immunodominant epitopes, identifying the critical aa residues of the known and unknown 107 epitopes, and defining their roles in generating neutralizing and non-nAbs will guide rational design and 108 construction of an efficacious EBV gp350-based vaccine that would focus B-cell responses to the protective 109 epitopes. 110
In this study, we generated 23 hybridomas producing antibodies against EBV gp350. To assess their 111 clinical potential and utility in informing future prophylactic and therapeutic vaccine design, we: (1) We determined the isotypes of the new antibodies to be IgG1 (n=14), IgG2a (n=5), IgG2b (n=1), a 131 mixture of IgG1 and IgG2b (n=1), and a mixture of IgG1 and IgM (n=2). We found that all 23 hybridomas that 132 produced antibodies (designated HB1-23) recognized the gp350 antigen in an initial ELISA screening using 133 unfractionated and unpurified hybridoma supernatants (data not shown). We used affinity purification with 134 protein A followed by SDS-PAGE to confirm the purity of all 23 antibodies. When we re-evaluated quantified 135 amount of the purified antibodies (10 g/ml) using indirect ELISA, all of the 23 antibodies had ELISA signals 136 two times greater than those of phosphate buffered saline (negative control), and were considered as positive or 137 specific to gp350. Of these, five (HB4, HB5, HB7, HB13, and HB14) demonstrated binding affinity equal to or 138 greater than that of the positive control, nAb-72A1 (Fig. 1A) . This difference in binding of the 23 antibodies 139 could be due to differential exposure of cognate epitopes on gp350 in the assay performed. 140
Determining the nature of the binding between an antibody and its target antigen is an important 141 consideration for the performance and specificity of an antibody, as it can involve the recognition of a linear or 142 conformational epitope (26). We characterized the antibodies using immunoblot analysis of denatured gp350 143 antigen expressed from Chinese hamster ovary (CHO) cells, and showed that 16 of the antibodies reacted to 144 both the 350 kDa and the 220 kDa splice variant. In contrast, HB2, HB3, HB6, HB7, HB13, HB20, and HB21 145 failed to recognize either of the denatured isoforms of gp350 (Fig. 1B) . We further characterized the antibodies 146 using flow cytometric analysis of CHO cells stably expressing gp350 on the cell surface, and revealed that HB1, 147 HB2, HB3, HB5, HB6, HB9, HB11, HB12, HB15, HB17, HB19, HB20, and HB21 antibodies readily 148 recognized gp350 (Fig. 1C) . Given that HB2, HB3, HB20, and HB21 detected gp350 by flow cytometry, but 149 not by immunoblot, suggests that these four antibodies recognized conformational epitopes (native) on gp350, 150 whereas HB5, HB9, HB11, HB15, HB17, and HB19 recognized both linear and conformational epitopes ( Fig.  151 1B-C). The observation that all 23 anti-gp350 antibodies recognized the gp350 antigen either by indirect 152 ELISA, flow cytometry, or immunoblot assay suggests that we successfully produced antibodies that are 153 specific to EBV gp350 protein.
154
Analysis of the variable heavy and variable light chain sequences. We determined the sequences of the 155 heavy and light chain variable region genes (V H and V L , respectively) of the 23 new anti-gp350 antibodies, as 156 well as nAb-72A1, and compared the sequences to published nAb-72A1 sequences (10, 33). The sequence of 157 the CDR of this antibody was recently determined and published, revealing two unique IgG1 heavy chains and 158 two unique light chains, one kappa and one lambda (10, 33). We used PCR to amplify the genes encoding the 159 V H and V L chain regions in cDNA generated from the 23 hybridoma cells, as well as from HB168 (nAb-72A1). 160
The PCR products presented distinct bands at approximately 350-400 bp and 450-500 bp for V H and V L , 161 respectively (data not shown). We sequenced purified fragments using Illumina MiSeq, followed by in silico 162 analysis and identified CDRs for both V H and V L (Fig. 2 ). We identified two V H and V L sequences of nAb-163 72A1 as >94% identical to the previously published sequences (10), suggesting that nAb-72A1 exists as a 164 mixed antibody, instead of the reported mAb (33). Similar to nAb-72A1, HB4, HB13, HB15, and HB23 165 hybridomas each produced a mixture of two antibodies, with unique sequences of the V H chain showing at >5% 166 frequencies, suggesting that they are not mAbs ( Table 1) . We were unable to identify coding sequences for V L 167 chains for HB7, HB9, and HB17, unless the frequencies were lowered to >1% (Table 1) ; in this case, the 168 identified coding V L chain sequences were identical. 169
Our analysis and comparison of the V H and V L chain gene sequences of the 23 hybridomas compared to 170 HB168 (nAb-72A1) showed unique sequences within the CDR 1-3 regions. Only HB8 and HB18 had identical 171 V H and V L chain gene sequences, suggesting that the two are the same clone isolated separately; therefore, 172 HB18 was excluded from subsequent experiments. One of the two HB15 antibodies had identical V H and V L 173 gene sequences to that of HB10; however, based on the previous characterization, the presence of the additional 174 antibody in HB15 was sufficient to confer subtle differences in biochemical characterizations for gp350 175 between the two antibodies. Thus, sequence analysis (Fig. 2 ) demonstrated that we generated 15 unique anti-176 gp350 mAbs, with distinct biochemical properties and sequence identities from the commercially available 177 nAb-72A1. 178
Neutralization assay. We evaluated the ability of the 15 mAbs (10 µg/ml or 50 µg/ml) to neutralize 179 purified eGFP-tagged AGS-EBV infection of the Raji B cell line in vitro following standardized procedures 180 (25) and determined the percentage of eGFP+ cells using flow cytometry as described (17, 18). We used the 181 nAbs 72A1 and anti-gH/gL (E1D1) as positive controls, whereas the non-neutralizing mAb 2L10 was used as a 182 negative control. Because HB4, HB7, HB13, HB15, HB16, HB19, HB21, and HB23 were confirmed to be 183 mixtures based on isotyping or sequence data, we eliminated them from further consideration in the 184 neutralization assay. We considered an antibody to be a neutralizer if it inhibited EBV infection >20% at 10 185 µg/ml and >60% at 50 µg/ml. Several mAbs inhibited EBV infection in a dose-dependent manner. HB20 and 186 HB17 were the most effective in neutralizing EBV infection of Raji cells in vitro, whereby they reduced 187 infection by 40% and >60%, and >30% and 80%, at 10 µg/ml and 50 µg/ml, respectively (Fig. 3) . The HB9 and 188 HB10 antibodies prevented EBV infection of Raji cells by ~25% at 10 µg/ml and ~60% at 50 µg/ml. The HB11 189
antibody neutralized <20% at 10 µg/ml, but showed a dose-dependent increase at 50 µg/ml by neutralizing EBV 190 infection by 60%. By the set neutralization parameters, HB1-3, HB5-8, HB12, HB14, and HB22 did not 191 neutralize EBV infection of Raji cells. In comparison, both nAb-72A1 and nAb-E1D1 neutralized EBV 192 infection by >70% and 40%, respectively, at 10 µg/ml. The nAb-72A1 neutralized 100% of EBV infection at 50 193 µg/ml, whereas nAb-E1D1 neutralized infection by >60% at 50 µg/ml. Analysis of V H -V L sequences from the HB168 (nAb-72A1) hybridoma by our group and others revealed 223 that the hybridoma produces two antibodies: one that is gp350-specific and another that recognizes mineral oil-224 induced plasmacytoma (MOPC)(10). To further interrogate gp350 for additional neutralizing epitopes, we used 225 the gp350-specific nAb-72A1 V H -V L sequence to generate chimeric (mouse/human) recombinant antibodies. 226
Similarly, we used the V H -V L sequence for the HB20 antibody, which our neutralization analysis above showed 227 to be one of the most effective nAbs, to generate chimeric antibodies. We generated a negative control chimeric 228 recombinant antibody using V H -V L sequences from the gp350-specific but non-neutralizing HB5 antibody 229 described above (Fig. 3) .
230
We performed comparative analysis of the epitope binding pattern using the chimeric recombinant 231 antibodies and revealed a novel epitope, 381 GAFASNRTFDIT 392 , which was bound by HB20 and nAb-72A1, 232 but not by HB5, and is distinct from the 145 EMQNPVYLIPETVPYIKWDN 164 epitope, which is bound only by 233 the nAb-72A1 (Fig. 5) In this study we generated 23 hybridomas producing gp350-specific antibodies and characterized their 247 ability to bind gp350 protein (Fig. 1) . Out of the 23 hybridomas, we determined that 15 were monoclonal and 248 novel based on their V H and V L CDR sequences, compared to the reported sequence of nAb-72A1 (22) (Fig. 2) 
249
Following confirmation that the new mAbs recognized EBV gp350 antigen and contained unique V H -V L 250 sequences, our further characterization revealed that mAbs HB9, HB10, HB11, HB17, and HB20 inhibited EBV 251 infection in a dose-dependent manner, with HB17 and HB20 being the best neutralizers (Fig. 3) . Thus, our 252 study provides new neutralizing and non-nAbs against EBV infection, which could potentially inform future 253 EBV vaccine research. 254
Various methods, including lectin/ricin immune-affinity assay (34), purified mAbs (1, 22), purified 255 soluble gp350 mutants, synthetic peptides (15, 16, 33) , cell binding assays (35), and crystal structure of partial 256 gp350 protein (aa 4-443) (30), have been used to identify the critical gp350 epitopes responsible for its 257 interaction with the CD35 and CD21 cellular receptors (for a detailed summary review see Table 3 ). We used 258 an epitope mapping assay to identify a total of nine epitopes, including two new epitopes, and one bound by all 259 mAbs, including nAb-72A1 and 2L10, regardless of the mAb neutralizing capability to EBV infection. This 260 suggests it is an immunodominant epitope on the gp350 protein. We further identified portions of four of the 261 previously described epitopes, including the only currently recognized neutralizing epitope, and defined their 262 exact aa residues. However, we could not identify two previously reported epitopes located at aa 282-301 and 263 aa 194-211, which have been reported to be involved in the binding of nAb-72A1 or CD21, respectively (30, 264 33, 35) (Fig. 4) .
265
Our comparative epitope mapping analysis results identified a novel neutralizing epitope, 266 381 GAFASNRTFDIT 392 , which was bound preferentially by the nAbs HB20 and nAb-72A1, but not the non-267 neutralizing mAb HB5 (Fig. 5) . The new neutralizing epitope is distinct from the reported canonical nAb-72A1-268 binding epitope aa 145-164, on gp350, suggesting that epitope 381-392 is a novel epitope on gp350 that might 269 be capable of eliciting nAbs. 270
In conclusion, in this study we generated 15 novel EBV gp350-specific mAbs, characterized their binding 271 to gp350, determined their neutralization activity against EBV infection in vitro, mapped their cognate epitopes, 272 and defined the exact aa residues they recognize on gp350. We confirmed six of the eight previously described 273 epitopes responsible for generating neutralizing and non-nAbs and defined the exact aa residues they bind. This 274 study also confirmed that the binding epitopes on gp350 that elicit nAbs are between aa 4-443 (30). We 275 identified an additional neutralizing epitope and two new non-neutralizing epitopes, with one located 276 downstream of the gp350 ectodomain (aa 1-841 The construction of the pCI-puro vector and pCAGGS-gp350/220-F has been described (17, 20). 302
Virus production and purification. eGFP-tagged EBV was produced from the EBV-infected AGS cell 303 line as described (29). Briefly, EBV-AGS cells were seeded to 90% confluency in T-75 flasks in Ham's F-12 304 medium containing G418 antibiotic. After the cells reached confluency, G418 media was replaced with Ham's 305 F-12 medium containing 33 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA) and 3 mM sodium butyrate 306 (NaB) to induce lytic replication of the virus. Twenty-four h post-induction, the media was replaced with 307 complete Ham's F-12 media without G418, TPA, or NaB and cells were incubated for 4 days at 37C. The cell 308 supernatant was collected, centrifuged, and filtered using a 0.8-µm filter to remove cell debris. coated with 50 µl of 0.5 µg/ml recombinant EBV gp350/220 (Millipore) protein diluted in phosphate buffered 327 saline (PBS, pH 7.4) and incubated overnight at 4°C. After washing three times with PBS containing 0.05% 328 (v/v) Tween 20 (washing buffer), plates were blocked with 100 µl washing buffer containing 2% (w/v) bovine 329 serum albumin (BSA), incubated for 1 h at room temperature, and washed as above. 100 µl of hybridoma 330 supernatant was added to each well (in triplicate) and incubated for 2 h at room temperature. PBS and nAb-331 72A1 were added as negative and positive controls, respectively. The plates were washed as described above, 332 followed by incubation with goat anti-mouse IgG horseradish peroxidase-conjugated secondary antibody 333
(1:2,000 diluted in PBS) at room temperature for 1 h. The plates were washed again and the chromogenic 334 substrate 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) (ABTS, Life Science Technologies) was 335 added. The reaction was stopped using ABTS peroxidase stop solution containing 5% sodium dodecyl sulfate 336 (SDS) in water. The absorbance was read at an optical density of 405 nm using an ELISA reader (Molecular 337 Devices). Three independent experiments were performed. 338
Antibody purification, quantification, and isotyping. Hybridoma cells from selected individual positive 339 clones were expanded stepwise from 96-well plates to T-75 flasks. At confluence in T-75 flasks, supernatant 340 from individual clones was collected, clarified by centrifugation (4,000 g, 10 min, 4°C), and filtered through a 341 0.22-μm-membrane filter (Millipore). Antibodies were further purified using Capturem™ Protein A Maxiprep 342 (Takara) and stored in PBS (pH 7.4) at 4 o C. Antibodies were analyzed by SDS-PAGE to determine purity. 343
Bicinchoninic acid assay (BCA assay; Thermo Fisher Scientific) was conducted to determine the concentration 344 of purified antibodies. Isotype identification was performed with the Rapid ELISA mouse mAb isotyping kit 345 (Thermo Fisher Scientific). 346 RNA extraction, cDNA synthesis, and sequencing of the variable region of the mAbs. Total RNA was 347 extracted from 1x10 6 hybridoma cells using the RNeasy Mini Kit (Qiagen). Each hybridoma clone cDNA was 348 synthesized in a total volume of 20 µl using Tetro Reverse Transcriptase (200 u), RiboSafe RNase Inhibitor, 349
Oligo(dT)18 primer, dNTP mix (10 mM each nucleotide), and 100-200 ng RNA. Reverse transcription was 350 performed at 45 o C for 30 min, and terminated at 85C for 5 min. The cDNA was stored at -20C. 351 Immunoglobulin (Ig) V H and V L were amplified using the mouse Ig-specific primer set purchased from 352
Novagen (12). The V H and V L genes were amplified in separate reactions and PCR products were visualized on 353 1% agarose gel. 354
The V H and V L amplicons were sequenced using an Illumina MiSeq platform: duplicate 50 μl PCR 355 reactions were performed, each containing 50 ng of purified cDNA, 0.2 mM dNTPs, 1.5 mM MgCl 2 , 1.25 U 356
Platinum Taq DNA polymerase, 2.5 μl of 10x PCR buffer, and 0.5 μM of each primer designed to amplify the 357 V H and V L . The amplicons were purified using AxyPrep Mag PCR Clean-up kit (Thermo Fisher Scientific). 358
The Illumina primer PCR PE1.0 and index primers were used to allow multiplexing of samples. The library was 359 quantified using ViiA™ 7 Real-Time PCR System (Life Technologies) and visualized for size validation on an 360
Agilent 2100 Bioanalyzer (Agilent Technologies) using a high-sensitivity cDNA assay. The sequencing library 361 pool was diluted to 4 nM and run on a MiSeq desktop sequencer (Illumina). The 600-cycle MiSeq Reagent Kit 362 (Illumina) was used to run the 6 pM library with 20% PhiX (Illumina), and FASTQ files were used for data 363 analysis(19). 364
Chimeric mAb construct generation. To generate chimeric mAbs, the V H and V L sequences were cloned 365 into the dual-vector system pFUSE CHIg/pFUSE CLIg (InvivoGen), which express the constant region of the 366 heavy and light chains of human immunoglobulins, respectively (Genewiz). The constructs were transiently 367 transfected into HEK-293 6E cells. The supernatants were collected at 72 h post-transfection and IgG was 368 purified using protein A/G affinity chromatography. 369
Immunoblot analysis. CHO cells were cultured and stably co-transfected with pCAGGS-gp350/220 F 370 and pCI-puro vector containing a puromycin resistance gene. Forty-eight h post-transfection, DMEM media 371 containing 10 µg/ml of puromycin was added to enrich for cells expressing gp350 protein. Puromycin-resistant 372 clones were expanded, followed by flow cytometry sorting using nAb-72A1 to a purity >90%. EBV gp350-373 positive CHO cells were harvested and lysed in radioimmunoprecipitation assay buffer (RIPA) followed by 374 centrifugation at 15,000 g for 15 min on a benchtop centrifuge. The supernatants were collected and heated at 375 95°C for 10 min in SDS sample buffer containing β-mercaptoethanol, then separated using SDS-PAGE. 376
Proteins were transferred onto a nitrocellulose membrane using an iBlot™ Transfer System (Thermo Fisher 377 Scientific) followed by incubation in blocking buffer (1% BSA; 20 mM Tris-HCl, pH 7.5; 137 mM NaCl; and 378 0.1%Tween-20 [TBST]) for 1 h. The blots were incubated in TBST containing purified anti-gp350 antibodies 379
(1:50) overnight at 4C. After three washes with TBST, the blots were incubated with a goat anti-mouse 380 conjugated to horseradish peroxidase (1:2,000) in TBST for 1 h. After three washes, the antibody-protein 381 complexes were detected using the Amersham ECL Prime Western Blotting Detection Reagent (GE 382 Healthcare). All experiments were independently repeated three times. 383
Flow cytometry. To assess the ability of purified anti-gp350 mAb to detect surface expression of EBV 384 gp350 protein by flow cytometry, CHO cells that stably express EBV gp350 were harvested and stained with 385 purified anti-gp350 (10 g/ml), followed by AF488 goat anti-mouse IgG secondary antibody. Flow cytometric 386 analysis was performed on a C-6 FC (BD Biosciences) and data was analyzed using FlowJo Cytometry 387
Analysis software (FlowJo, LLC) as described (18). All experiments were independently repeated three times. 388 EBV neutralization assay. Purified individual anti-gp350 mAbs were incubated with purified AGS-389 EBV-eGFP (titer calculated to infect at least 20% of HEK293 cells seeded in 100 μl of serum-free DMEM) for 390 2 h at 37°C. To represent EBV infection of B cells, the pre-incubated anti-gp350 mAbs/AGS-EBV-eGFP were 391 used to infect 5x10 5 Raji cells seeded in a 96-well plate. Anti-gp350 neutralizing 72A1 and non-neutralizing 392 2L10 mAbs served as positive and negative controls, respectively. Plates were incubated at 37°C and the 393 number of eGFP+ cells was determined using flow cytometry 48 h post-infection. All dilutions were performed 394 in quintuplicate and the assays repeated three times for Raji cells. Antibody EBV neutralization activity was 395 calculated as: % neutralization = (EBValone-EBVmAb) / (EBValone) x 100. 396
Epitope mapping. Anti-gp350 mAbs were incubated with a multi-well EBV GP350/GP340 RepliTope 397 (JPT) peptide microarray displaying 224 peptides (15-mers with 11 aa overlap) in 3x7 subarrays. Briefly, anti-398 gp350 mAbs were diluted in blocking solution (TBS-T and 2% BSA) to a final concentration of 10 g/ml and 399 incubated with the microarray slide for 1 h at 30C with shaking. Slides were washed 5 times with wash buffer 400 (TBS-T), followed by incubation with 1 µg/ml secondary antibody Dylight 650 (Thermo Fisher Scientific) for 1 401 h at 30C. After washing 5 times with wash buffer and 2 times with distilled water, microarray slides were dried 402 by centrifugation. Detection was performed using the Agilent DNA microarray scanner. 
